aplastic anemia
Conditions
Interventions
Trial group:In the pre-treatment process, the drug (BU) is only used for one day in the trial group
Control group:In the pre-treatment process, the drug (BU) is used for standard two days in the control group
Sponsors
Huazhong University of Science Tongji Hospital, Tongji Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Age 18-60; 2) Gender: male or female; 3) Related allogeneic hematopoietic stem cell transplantation healthy donor; 4) Weight >=40kg; 5) The general condition is OK, ECOG score=50%; 7) Normal liver and kidney function: blood bilirubin <=35µmol/L, AST/ALT less than 2 times the upper limit of normal value, serum creatinine <=130µmol/L; 8) Subjects sign informed consent.
Exclusion criteria
Exclusion criteria: 1) Unrelated allogeneic hematopoietic stem cell transplantation; 2) ECOG >2; 3) Severe infection before mobilization that was not controlled; 4) Patients with renal insufficiency (creatinine>=176.8lmol/l); 5) Hepatic insufficiency (total bilirubin>34.2umol/L, ALT, AST>=3 times the upper limit of normal); 6) Patients with cardiac insufficiency (left ventricular ejection fraction12.95mmol/l or triglyceride>5.65mmol/l and positive human immunodeficiency virus seroreaction despite appropriate treatment; 8) Pregnant or lactating women; 9) Known infection with human immunodeficiency virus (HIV); 10) Other situations that do not meet the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidence of engraftment; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival rate;failure-free-survival rate; | — |
Countries
China
Contacts
Public ContactDonghua Zhang
Huazhong University of Science Tongji Hospital, Tongji Medical College
Outcome results
None listed